Lannett Co. has received approval from the Food and Drug Administration for loxapine capsules, an anti-psychotic medication.


Lannett, loxapine capsules, Loxitane generic, Loxitane, anti-psychotic medication, generic pharmaceutical, Watson Pharmaceuticals, Arthur Bedrosian






































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Lannett to ship Loxitane generic

September 27th, 2011

PHILADELPHIA – Lannett Co. has received approval from the Food and Drug Administration for loxapine capsules, an anti-psychotic medication.

The generic pharmaceutical company said Tuesday that the loxapine capsules will be available in strengths of 5 mg, 10 mg, 25 mg and 50 mg. 

According to Lannett, the product is therapeutically equivalent to the reference listed drug, Loxitane Capsules (5 mg, 10 mg, 25 mg and 50 mg) from Watson Pharmaceuticals.

Lannett said it expects to begin shipping the loxapine capsules in the next few weeks.

Retail pharmacy sales of loxapine capsules at average wholesale price (AWP) were about $22.3 million for the 12 months ended in June, according to Wolters Kluwer data cited by Lannett.

"We have now received five product approvals from the FDA over the last three months," stated Arthur Bedrosian, president and chief executive officer of Lannett. "Loxapine capsules are an important addition to our product lineup."

Advertisement